Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (Q29620657)

10 January 2018

title

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma (English)

1 reference

10 January 2018

0 references

Caroline Robert

0 references

Jedd D. Wolchok

object named as

Jedd D Wolchok

1 reference

10 January 2018

F Stephen Hodi

object named as

F Stephen Hodi

1 reference

10 January 2018

Michael A Postow

object named as

Michael A Postow

1 reference

10 January 2018

author name string

Jason Chesney

1 reference

10 January 2018

Anna C Pavlick

1 reference

10 January 2018

Kenneth Grossmann

1 reference

10 January 2018

David McDermott

1 reference

10 January 2018

Gerald P Linette

1 reference

10 January 2018

Nicolas Meyer

1 reference

10 January 2018

Jeffrey K Giguere

1 reference

10 January 2018

Sanjiv S Agarwala

1 reference

10 January 2018

Montaser Shaheen

1 reference

10 January 2018

Marc S Ernstoff

1 reference

10 January 2018

David Minor

1 reference

10 January 2018

April K Salama

1 reference

10 January 2018

Matthew Taylor

1 reference

10 January 2018

Patrick A Ott

1 reference

10 January 2018

Linda M Rollin

1 reference

10 January 2018

Christine Horak

1 reference

10 January 2018

Paul Gagnier

1 reference

10 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=25891304

language of work or name

1 reference

30 April 2017

publication date

20 April 2015

1 reference

10 January 2018

The New England Journal of Medicine

published in

1 reference

10 January 2018

volume

372

1 reference

10 January 2018

issue

1 reference

10 January 2018

page(s)

2006-2017

1 reference

10 January 2018

PD-1 blockade induces responses by inhibiting adaptive immune resistance

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Nivolumab in previously untreated melanoma without BRAF mutation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Improved overall survival in melanoma with combined dabrafenib and trametinib

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Nivolumab plus ipilimumab in advanced melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5744258

26 November 2018

Identifiers

DOI

10.1056/NEJMOA1414428

1 reference

10 January 2018

OpenCitations bibliographic resource ID

608722

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

10 January 2018

PubMed publication ID

25891304

1 reference

10 January 2018